SUMMARY We examined the ability of the angiotensins (A I, A II, A III) to release a prostaglandin E (PGE)-like substance in the isolated Krebs' perfused kidney and mesenteric vasculature of the rabbit by parallel bioassay. In the kidney, the order of potency for PGE release was A II > A III > A I with EI) 5l ,'s of 36, 100, and 500 pmol, respectively. In the mesenteric preparation, on the other hand, the order of potency was A III > A II > A I with ED 5ll 's of 75,125, and 500 pmol, respectively. During one transit through the kidney 72-76% of bioassayable A I and A II was degraded. A III was 89% metabolized. In contrast, the mesenteric vasculature inactivated only 27% of A II and 23% of A HI. This data suggests an inverse relationship between renal peptide degradation and PGE release. (1) A III has only 25-50% the pressor activity of A II, (2) A III is an equipotent or a more potent stimulus of aldosterone biosynthesis than A II, 2 " 7 (3) A III produces a decrease in plasma renin activity similar to that caused by A II, 2 ' 7~9 (4) A III is more potent than A II in stimulating tyrosine hydroxylase in adrenergic nerves and brain, 1 " and (5) A II is more potent than A III in evoking adrenal catecholamine release." These observations suggest that A III may be an important agonist in its own right. Furthermore, based on the above studies,'" 9 it has been suggested that angiotensin receptors differ in vascular smooth muscle and the adrenal cortex. In support of this hypothesis is the finding that A II antagonists with substitution in the 8 position are potent competitive inhibitors of A II-induced contraction of smooth muscle, but these same antagonists are relatively poor inhibitors of A II and A Ill-induced adrenal steroidogenesis in vivo.
RECENT EVIDENCE concerning [des-Asp']-angiotensin II (angiotensin III, A III) has demonstrated that (1)
A III has only 25-50% the pressor activity of A II, (2) A III is an equipotent or a more potent stimulus of aldosterone biosynthesis than A II, 2 " 7 (3) A III produces a decrease in plasma renin activity similar to that caused by A II, 2 ' 7~9 (4) A III is more potent than A II in stimulating tyrosine hydroxylase in adrenergic nerves and brain, 1 " and (5) A II is more potent than A III in evoking adrenal catecholamine release." These observations suggest that A III may be an important agonist in its own right. Furthermore, based on the above studies,'" 9 it has been suggested that angiotensin receptors differ in vascular smooth muscle and the adrenal cortex. In support of this hypothesis is the finding that A II antagonists with substitution in the 8 position are potent competitive inhibitors of A II-induced contraction of smooth muscle, but these same antagonists are relatively poor inhibitors of A II and A Ill-induced adrenal steroidogenesis in vivo. 12 " 14 In contrast an A III antagonist ([Ile 7 ]-A III) is a potent competitive inhibitor of the steroidogenic effect of both A II and A III," but is a relatively ineffective inhibitor of A II-induced elevations of blood pressure. 11 It has been reported that A I, A II, and bradykinin induce PGE release in the isolated, Krebs" perfused rabbit kidney.
151 " In a preliminary report 17 we have found A III to be more potent than A II for inducing PGE release Received September 9. 1976; accepted for publication January 19, 1977. from the mesenteric vasculature. In view of the different relative potencies of A III and A II in vascular smooth muscle (A II > A III), adrenal cortex (A III 2: A II), and adrenal medulla (A II > A III), in the present investigation we have assessed the relative potencies of A I, A II, and A III in evoking renal and mesenteric PGE release. Factors influencing relative potencies such as peptide degradation and receptor affinities for these agonists were also assessed.
Methods

RABBIT KIDNEY PERFUSION
Male New Zealand rabbits weighing 1.5-2 kg were anesthetized with pentobarbital sodium (30 mg/kg, iv). After opening the abdominal cavity, the rabbit was heparinized (250 U/kg) and the renal artery was cannulated with a polyethylene catheter (PE-160, Clay-Adams). The kidney was placed in a warming jacket and perfused at a constant flow (13 ml/min) with Krebs' solution at 37°C gassed with 95% O 2 and 5% CO 2 .
RABBIT MESENTERY PERFUSION
Rabbits were anesthetized, heparinized, and their abdominal cavities opened as described above. The superior mesenteric artery 2 cm distal to the aorta was cannulated with a polyethylene catheter (PE-160, Clay-Adams). The vessels of the mesenteric vascular bed were severed close to the intestine and perfused with Krebs 7 solution (95% O 2 , 5% CO 2 , 37°C) at 10 ml/min as described by McGregor. was superfused by the effluent from the perfused organ (kidney or mesenteric vasculature) according to the procedure of Vane . l9 The rat stomach strip and chick rectum are particularly sensitive to PGs of the E series while the rabbit aorta, rat colon, and rat stomach strip are sensitive to the angiotensins. A mixture of antagonists was added to the superfusion fluid to render the assay tissues insensitive to catecholamines, acetylcholine, serotonin, and histamine. 20 Indomethacin (10 /Mg/min) also was perfused directly over the assay organ to inhibit endogenous PG release and to enhance the sensitivity of the assay organs to PGs. 21 Substances were tested (as a bolus injection) for their direct effect on the assay organs by adding the agent to the perfusion fluid after it had passed through the perfused organ.
The response of the perfused organ to the drug was determined by injecting the agent into the Krebs' solution through an injection port just proximal to the organ. 
CHROMATOGRAPHIC IDENTIFICATION OF PROSTAGLANDIN-LIKE MATERIAL
The substances detected in both the renal and mesenteric effluent were assumed to be prostaglandin E (PGE). This was based on (1) the specificity of the bioassay system used 22 and (2) the disappearance of activity after treatment with indomethacin, a specific inhibitor of PG synthesis. Confirmation that the prostaglandin-like material released from both isolated perfused organs and detected by the bioassay organs was predominantly PGE was obtained by extraction and thin-layer chromatography as follows: samples of the effluent were acidified to pH 3.5 with formic acid and extracted twice with ethyl acetate 75 ml. The organic phase was evaporated in vacuo and applied to silica gel G thin layer plates and chromatographed in chloroform-methanol-acetic acid-water (90:8:1:0.8).
Zones of the chromatograms corresponding to standard PGF and PGE were scraped, eluted with methanol, and concentrated under a stream of N 2 . The extracts were then dissolved in 0.9% saline and bioassayed on a chick rectum and a rat stomach. All bioassayable contractile activity of either renal or mesenteric angiotensin-induced PG release resided in the zones corresponding to standard PGE. PGE, and PGE 2 are not distinguishable in this solvent system.
DETERMINATION OF PEPTIDE DESTRUCTION
Peptide degradation during one transit through the perfused kidney and mesenteric vasculature was determined (Table 1 ) by comparing the concentration of angiotensin required to produce fixed contractions of the rat stomach strip when administration was through the organ (e.g., through the kidney is TK) and directly over the stomach strip (DIR). Indomethacin was infused through the organ 
± 3t 23 ± 2t
Results are expressed as mean ± SEM. * P < 0.05 compared to A II or A I. t P < 0,05 compared to renal destruction of same peptide.
during these experiments to inhibit PG synthesis and thus eliminate any PG-induced contraction of the rat stomach strip. Percent destruction was determined as follows for fixed contractions (1 cm, 2 cm) of the rat stomach strip, e.g.:
An interval of 20 minutes was allowed between successive administration of peptides to avoid the development of tachyphylaxis. 
EXPERIMENTS WITH ANGIOTENSIN ANTAGONISTS
Results are expressed as mean ± SEM.
renal artery, A II was the most potent stimulant of PGE release, with an ED 50 * of 36 pmol; less potent were A III (ED 50 = 100 pmol) and A I (ED 50 = 500 pmol). Compared on a weight basis (ng) A II-induced PGE release was significantly greater than A Ill-induced release at 25, 50, and 100 ng (P < 0.05). Renal PGE release from injection of A I is not the result of conversion to A II, since a converting enzyme inhibitor did not alter the response. 15 In contrast, the order of potency for PGE release from the perfused mesenteric vasculature was A III > A II > A I, with ED 50 's of 75, 125, and 500 pmol, respectively. A III produced a significantly greater mesenteric PGE release than A II at 50 and 100 ng (P < 0.05). Approximately 10% of A I is converted to A II in the rabbit mesenteric preparation; 23 therefore the A I-induced PGE release from the mesentery (Fig. 1) is due partially to conversion to A II.
METABOLISM OF ANGIOTENSINS IN PERFUSED KIDNEY AND MESENTERY
To investigate whether the different order of potency of the angiotensins in evoking renal and mesenteric PGE release might be due to differential peptide destruction, the percent destruction of each angiotensin was determined. Figure 2 illustrates the dose-response curves of the peptides for evoking contraction of the rat stomach strip (RSS) when administered directly (DIR) to the strip or through an indomethacin treated kidney (TK). Similar experiments were performed with indomethacin treated mesenteric preparations. From Table I the following can be discerned: (1) significantly more A III than A I or A II is destroyed in the kidney and (2) mesenteric peptide destruction is significantly less than renal destruction with no notable difference between A II and A III. 
Discussion
The primary finding of our study is that A III is a potent stimulus for renal as well as mesenteric PGE release. A II and A III influence a variety of angiotensin receptors in a qualitatively similar manner; 2 namely, both have similar steroidogenic potency and inhibitory action against renin release in vivo, In view of these findings suggesting that angiotensin receptors have different affinities for A II and A III, the renal angiotensin receptor which mediates PGE release was studied. Figure 1 shows that A III is about 37% as potent and A I about 7% as potent as A II in evoking renal PGE release. The order of potency is quite different in the mesenteric vasculature with A II being 69% and A I 21% as potent as A III. The data on PGE release agrees with an earlier report from this laboratory that demonstrated (1) A I-induced renal PGE release occurred without conversion to A II, (2) mesenteric A I-induced PGE release was * In these studies the term EDj,, is defined as the effective dose that elicits 50% of the maximum effect obtainable within the dose range examined. about 20% that of A II, and (3) A I exerts only 1 % of the direct action of A II on the rat stomach strip. 15 Recent evidence does suggest, however, that conversion of A I to A II may occur by enzymes other than converting enzymes. 26 A direct action of A I (as with renal PGE-release) without conversion to A II has been demonstrated in the feline adrenal medulla where A I is equipotent to A II in evoking catecholamine release, while A III is 16.7% as potent as A I or A II."
Perhaps a differential destruction of the three angiotensin peptides may account for the differing renal and mesenteric orders of potency we obtained, and that obtained in the adrenal medulla by Peach et al." Substantially more A III than A I or A II was destroyed during one transit through the kidney, while the mesentery exhibited a rather small but equivalent destruction of both A I and A III (Table 1) . If peptide destruction occurred proximal to the angiotensin-PGE receptor site, this might account for the order of potency obtained. From this assumption, the effective ED 50 concentration reaching the receptor site would be: All = 10 ng, A III = 11 ng, and A I = 120 ng. Thus, the critical question still remaining is the actual site of angiotensin destruction.
Use of isolated Krebs perfused organs eliminates the contribution of plasma angiotensinases to the metabolism of angiotensins and thus leaves the possibilities of (1) tissue enzymatic catabolism of the hormone, (2) retention in the tissue of the hormone by binding to either specific or nonspecific receptors, or (3) diffusion into perivascular compartments. Osborne et al. 27 demonstrated that 3 Hangiotensin II is degraded to a considerable extent during its passage through the renal vascular bed and is not retained in the tissues. Goodfriend and Peach 6 have shown that A II is more resistant to degradation than A III in adrenal glomerulosa cells in vitro. From our data it appears that the renal angiotensinase and/or leucine aminopeptidase have a greater affinity for A III than for A II, but another possibility is that the heptapeptide (A III) is taken up within the renal vasculature in contrast to A II. 30 These values are similar to the K B values reported in Table 2 . These results suggest that the renal angiotensin receptor which mediates PGE release appears to be of a single type and similar to the vascular smooth muscle and adrenal medulla receptors.
A possible role of A I as a primary intrarenal hormone has been suggested by Itskovitz and McGiff. 31 These authors reported that A I may modulate inner cortical and medullary renal blood flow without being converted to A II. The results of the present investigation, as well as a previous report, 15 support this hypothesis since little conversion of A I to A II was observed and A I did evoke PGE release from the isolated perfused rabbit kidney.
PGE release from the isolated mesentery and kidney does not appear to result from the vascoconstriction produced by angiotensins because vasopressin produced an equivalent constriction of the preparations without evoking PGE release (P. Needleman and A. Blumberg, unpublished observations).
A possible pathophysiological role for angiotensin-induced renal PGE release is found in endotoxin shock in which the dilator PGE might overide the massive renal vasoconstriction caused by A II in the high renin state. In a canine model of endotoxemia, 32 angiograms of the mesenteric vasculature showed an initial and transient constriction followed by a marked and chronic dilation. Indomethacin (administered 60 minutes after endotoxin) decreased the renal and mesenteric vascular diameter during the endotoxemia. Although an angiotensin antagonist, when administered during the hypotensive phase (50 minutes after endotoxin), did not affect the above results, local angiotensin formation by the mesenteric vasculature 33 may be responsible for the initial constriction and A II-induced PGE release the secondary prolonged dilation. 23 In fact, the mesenteric vasculature of nephrectomized dogs was found to contain increased amounts of renin after hemorrhage. 33 Angiotensin-induced release of PGE from the mesentery also may be involved in the escape of intestinal resistance vessels to A II. 34 
